Q2 saw continued commercial growth, major new hospital agreements, and successful physician training. Despite a site-specific adverse event, investigation confirmed no device malfunction and no slowdown in business fundamentals. Company remains fully funded and focused on deepening utilization.
Based on EBR Systems Q2 2026 Audio Transcript — Jul. 31 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.